STAT Podcast Breaks Down Eli Lilly Deal Strategy, Allogene Off-the-Shelf CAR-T, and Merck Terns Acquisition
STAT News podcast analyzes Eli Lilly's deal-making, Allogene's allogeneic CAR-T progress, and Merck's purchase of Terns Pharmaceuticals.
In its latest episode of The Readout LOUD, STAT News examines three prominent themes in biopharma: the influence of Eli Lilly's key deal maker, Allogene Therapeutics' development of off-the-shelf allogeneic CAR-T therapies, and Merck's acquisition of Terns Pharmaceuticals. The discussion provides industry context on these business and clinical developments but does not present new peer-reviewed research, RCT data, observational studies, sample sizes, or conflict-of-interest disclosures. Source: https://www.statnews.com/2026/03/26/eli-lilly-allogene-merck-terns-readout-loud-podcast/
VITALIS: These big company deals point to a future where lifesaving treatments for serious illnesses like cancer become easier to produce and more widely available, rather than custom-made for each patient. For ordinary people, that could mean faster access to better options without sky-high costs in the years ahead.
Sources (1)
- [1]Eli Lilly’s deal man, Allogene’s off-the-shelf CAR-T, and Merck’s Terns buy(https://www.statnews.com/2026/03/26/eli-lilly-allogene-merck-terns-readout-loud-podcast/?utm_campaign=rss)